GRENOBLE, France and PRINCETON, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- Koelis, SAS (“Koelis” or the “Company”, www.koelis.com), a leader and innovator in prostate care, announced today a new partnership with Bot Image™ (Omaha, NE, USA) to serve the growing field of prostate “fusion biopsy” in the USA. The partnership will permit Koelis to combine its proprietary and accurate Trinity® MRI-fusion guidance system with the Bot Image ProstatID™ system, the first FDA-cleared software for screening, detection and diagnosis of prostate cancer using fully automated AI-based lesion detection, classification and 3D contouring.
Koelis will be holding live and interactive demos at its AUA booth #1259 from April 25th to 28th.
The Bot Image™ Partnership reinforces Koelis’ commitment to both prostate biopsy accuracy and workflow efficiency. The automated lesion detection and prostate segmentation features of ProstatID™ will facilitate radiologist workflow, while also enabling access to processed MRI’s by the Koelis Trinity® fusion guidance system. More specifically, the Koelis Trinity® direct access to ProstatID™ automated lesion detection and prostate segmentation data will allow urologists to create a 3D patient-specific prostate map for the guidance of both biopsy and focal treatment procedures. In addition to offering accuracy and workflow efficiency, the Koelis Trinity® is a compact system that does not require interfaces with either external ultrasound equipment or external sensors.
Dr. Jamil Syed, based at the Cleveland Clinic Indian River Hospital, Rosner Family Health & Well Center in Vero Beach FL., commented, “As a Urologist, the Koelis/Bot Image AI combination is a game changer. The automatic MRI-based lesion detection and prostate segmentation saves me time and adds confidence to my fusion biopsy plan.”
Dr. Randall Jones, CEO and founder of Bot Image noted, “The 93.6% sensitivity-specificity of ProstatID™ (AUROC) is unmatched by any other software product. Other AI products provide some level of physician aid to identifying suspect lesions, but ProstatID™ does the heavy lifting of segmentation and classification by providing physicians with a PI-RADS or Level-of-Suspicion (LOS) score as well as risk assessment score for each lesion along a continuous scale from 1-99.”
About KOELIS
Headquartered in Grenoble, France, Koelis has been a pioneer and leader of MRI-US fusion image guidance technology since 2006. Featuring proprietary 3D ultrasound and prostate motion tracking software (OBT Fusion®), the Koelis Trinity® system facilitates more accurate biopsy diagnosis as well as enabling “focal” prostate cancer treatment alternatives to traditional “total” organ treatments such as surgical prostatectomy and radiation. The Company’s commitment to minimally invasive prostate cancer treatment includes multi-center clinical registries (“Violette” in Europe, NCT04582656, and “Violetta” in Asia, NCT06262633) in Europe based on Trinity-guided microwave ablation technology. Koelis has offices in Grenoble (France), Princeton (NJ, USA), Saarbrücken (Germany) and Singapore to serve more than 50 countries. Learn more about KOELIS at www.koelis.com.
About BOT IMAGE, Inc.
Bot Image™ is a Nebraska and Maine based Artificial Intelligence (AI) medical device company. Founded in 2018, Bot Image’s mission is to blend AI with current diagnostic and image-guided technologies in order to bring about substantial improvements in prostate cancer clinical outcomes including screening, detection, classification, and grading of prostate lesions. The company’s ProstatID™ was FDA-cleared in 2022 and was first previewed at the AUA 2024 in San Antonio, Texas. Learn more about BOT IMAGE at www.botimageai.com.
For KOELIS media inquiries, please contact:
Thomas Martins-Pinheiro
Communication Manager
Phone: +33 (0)4 58 17 68 10
Email: thomas.martins-pinheiro@koelis.com
USA: Mark Rooney
Vice President & General Manager
Email: mark.rooney@koelis.com
Figure: Automatic AI-based 3D prostate and lesion contours as displayed in Koelis Trinity®.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6ece93da-a314-4b9f-a2f2-ea057b45420c
